Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Can Amgen, Inc. (AMGN) Thrive on Beating Melanoma?

Page 1 of 2

Amgen, Inc. (NASDAQ:AMGN)‘s stock has surged more than 44% over the past year, but while this big biotech has rewarded investors handsomely with a solid performance lately, it’s always in the hunt for the star pharmaceuticals of the future. The company reported solid clinical data from its developmental melanoma drug talimogene laherparepvec, or T-Vec, over the weekend as Amgen looks to forward the drug toward an eventual application.

Is melanoma really a market where Amgen, Inc. (NASDAQ:AMGN) can thrive, however? This company’s stock has blown up on blockbusters such as immunology drug Enbrel and neutropenia-fighting Neupogen, but T-Vec’s facing a different sort of competitive landscape. Could T-Vec provide Amgen’s next blockbuster? Let’s take a look at the latest from this promising treatment.

Hitting the right marks
Amgen, Inc. (NASDAQ:AMGN)First, let’s check out the latest with T-Vec. Amgen, Inc. (NASDAQ:AMGN) released interim phase 3 trial data for the drug over the weekend at the American Society for Clinical Oncology conference, which showed a 21% improvement in survival for patients as compared to a traditional therapy. T-Vec also proved to significantly reduce tumor growth as compared to standard therapies, an important point that will help Amgen’s quest to get this drug approved.

Amgen, Inc. (NASDAQ:AMGN) will report final data later in the year, but this interim report looks promising. Analyst Michael Yee from RBC Capital Markets predicted that T-Vec would need to show a 15% improvement in survival over standard treatments in order to garner approval. So far, so good.

Amgen, Inc. (NASDAQ:AMGN)’s stock didn’t react so positively to the news, however, as shares fell 1.4% on Monday. Are investors in the right, here, or is T-Vec’s potential understated?

First off, the melanoma drug market isn’t huge — yet. Research firm Decision Resources said last year that Roche‘s Zelboraf and Bristol Myers Squibb Co. (NYSE:BMY)‘s Yervoy, two immunotherapies approved in 2011 to treat melanoma, accounted for two-thirds of the malignant melanoma drug market. Yervoy picked up more than $700 million in sales last year, but Zelboraf only recorded around $250 million in revenue. That’s not a giant market to capitalize on.

Additionally, T-Vec has more competition hurrying into the market. GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s melanoma drugs Mekinist and Tafinlar were recently approved by the FDA, and analysts project that the two drugs could reach a combined $600 million in sales in 2016. Additionally, Merck & Co., Inc. (NYSE:MRK)‘s lambrolizumab hasn’t been approved by regulators yet, but the drug proved to reduce tumors in 38% of patients in early-stage trial results published at the ASCO meeting. Merck & Co., Inc. (NYSE:MRK) likely won’t have that drug approved any time soon, but it’s one to watch for Amgen, Inc. (NASDAQ:AMGN) investors or those taking note of the melanoma space.

Still, analysts are confident in T-Vec’s success should Amgen clinch regulatory approval. Early peak sales projections vary, but at least one analyst has estimated peak sales of $500 million for the drug.

Page 1 of 2